{
    "data": [
        {
            "id": "3574156",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-15T08:59:21-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Premarket Biotech Digest: Incyte Fairly Valued, Zafgen Bounces Back, Mylan's Perrigo Bid",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3574156-premarket-biotech-digest-incyte-fairly-valued-zafgen-bounces-back-mylans-perrigo-bid"
            }
        },
        {
            "id": "3511266",
            "type": "article",
            "attributes": {
                "publishOn": "2015-09-15T11:45:30-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "ECC Preview - Incyte And NewLink Pull Curtain Back On IDOs",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3511266-ecc-preview-incyte-and-newlink-pull-curtain-back-on-idos"
            }
        },
        {
            "id": "3476006",
            "type": "article",
            "attributes": {
                "publishOn": "2015-08-29T06:39:18-04:00",
                "isLockedPro": false,
                "commentCount": 923,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "SA Biotech Panel Discussion: Geron And Incyte, Imetelstat And Jakafi",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3476006-sa-biotech-panel-discussion-geron-and-incyte-imetelstat-and-jakafi"
            }
        },
        {
            "id": "3269945",
            "type": "article",
            "attributes": {
                "publishOn": "2015-06-19T08:04:45-04:00",
                "isLockedPro": false,
                "commentCount": 582,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Best Pairs Trade In The Market: Buy Geron And Short Incyte",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71935",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3269945-the-best-pairs-trade-in-the-market-buy-geron-and-short-incyte"
            }
        },
        {
            "id": "3267785",
            "type": "article",
            "attributes": {
                "publishOn": "2015-06-18T12:24:16-04:00",
                "isLockedPro": false,
                "commentCount": 110,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "High Time To Go Short Incyte Pharmaceuticals",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "88736",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "229689",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3267785-high-time-to-go-short-incyte-pharmaceuticals"
            }
        },
        {
            "id": "2950066",
            "type": "article",
            "attributes": {
                "publishOn": "2015-02-25T14:28:38-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Flexus Shows Other Immuno-Oncology Wannabes How It's Done",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2950066-flexus-shows-other-immuno-oncology-wannabes-how-its-done"
            }
        },
        {
            "id": "2864576",
            "type": "article",
            "attributes": {
                "publishOn": "2015-01-29T14:20:07-05:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Earnings Peek: Don't Expect Incyte To Be Profitable In 2014",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75375",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "149845",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2864576-earnings-peek-dont-expect-incyte-to-be-profitable-in-2014"
            }
        },
        {
            "id": "2793025",
            "type": "article",
            "attributes": {
                "publishOn": "2015-01-02T07:02:00-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Zacks' Bull Of The Day: Incyte",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20568",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "148057",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2793025-zacks-bull-of-the-day-incyte"
            }
        }
    ]
}